Immunome, Inc. (NASDAQ:IMNM) CTO Acquires $103,566.00 in Stock

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CTO Philip Tsai acquired 12,300 shares of Immunome stock in a transaction on Monday, March 24th. The stock was acquired at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the purchase, the chief technology officer now owns 33,300 shares of the company's stock, valued at approximately $280,386. The trade was a 58.57 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Immunome Trading Down 4.0 %

Shares of NASDAQ:IMNM traded down $0.29 during trading on Friday, hitting $6.99. 1,060,189 shares of the company's stock traded hands, compared to its average volume of 854,933. The company has a 50-day moving average price of $9.50 and a 200-day moving average price of $11.31. Immunome, Inc. has a 52 week low of $6.90 and a 52 week high of $24.87. The company has a market cap of $607.79 million, a price-to-earnings ratio of -0.86 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The company had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. On average, analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

Several research firms have recently issued reports on IMNM. Guggenheim reduced their price target on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Wedbush restated an "outperform" rating and set a $33.00 target price on shares of Immunome in a research report on Thursday, March 20th. Stephens reiterated an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Finally, Lifesci Capital started coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has a consensus rating of "Buy" and a consensus price target of $25.50.

Hedge Funds Weigh In On Immunome

A number of large investors have recently added to or reduced their stakes in IMNM. Enavate Sciences GP LLC acquired a new position in shares of Immunome during the fourth quarter worth about $36,939,000. JPMorgan Chase & Co. lifted its stake in Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock valued at $6,888,000 after acquiring an additional 624,045 shares in the last quarter. Janus Henderson Group PLC boosted its position in Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock worth $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Granahan Investment Management LLC acquired a new stake in shares of Immunome in the fourth quarter valued at approximately $3,337,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Immunome by 2,696.5% in the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock valued at $3,356,000 after purchasing an additional 304,700 shares during the last quarter. Institutional investors own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.